NEEDHAM, MA--(Marketwired - November 02, 2016) - Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute (CII), announces the acquisition of the Neurotech Investing and Partnering Conference and the European Neurotech Investing and Partnering Summit, two of the industry's premier business and investment conferences for commercial neuroscience.

The Neurotech Conference portfolio, created by NeuroInsights more than a decade ago, consists of the Neurotech Investing and Partnering Conference, an annual North American conference, as well as the European Neurotech Investing and Partnering Summit, a bi-annual European conference. The annual conference draws more than 200 of the top industry leaders focusing on the next generation treatments for Alzheimer's, addiction, anxiety, depression, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, Parkinson's and more.

Both events will continue to be co-organized by The Neurotechnology Industry Organization, which is the first and only trade group that advocates on behalf of companies involved in neurotechnology.

Phillips Kuhl, President, Cambridge Innovation Institute, says, "CHI has been providing life science conferences for twenty-five years, and we are very excited to expand our life sciences conference portfolio with the addition of Neurotech Partnering and Neurotech Europe, two high quality and established events. We plan to continue a strong relationship with the Neurotech Industry Organization to ensure continuity of the superb content and networking that attendees have come to expect over the last decade. Also, we are pleased to confirm an ongoing advisory relationship with Zack Lynch and Casey Lynch, the co-founders of NeuroInsights."

The Neurotech Conferences provide a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

"We wanted to be sure the Neurotech Conference portfolio would continue to have the quality, attention to detail, and key affiliations that have made it so successful. Over the years, we have watched many new relationships formed at these events that lead to successful new treatments and partnerships. We are confident that CHI will continue our tradition of excellence and work in concert with NIO to cultivate the things that make this conference so effective for the global commercial neuroscience community," said Zack Lynch and Casey Lynch, co-founders of NeuroInsights.

Allison Fenney, Executive Director of the Neurotechnology Industry Organization (NIO), agreed, "NIO is glad to have CHI as a new partner in co-hosting the North American and European conferences -- key events for our membership to connect with investors and potential partners as well as share lessons learned. The conference is an important time for NIO to share legislative and funding opportunities and identify issues impacting the industry as a whole and we look forward to a fruitful partnership."

Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices, software and diagnostics for the brain and nervous system.

For more information on either of these events, visit: http://neurotechpartnering.com

Neurotechnology Industry Organization (NIO) (www.neurotechindustry.org)
Since 2006, over 120 neuroscience organizations have joined the Neurotechnology Industry Organization in our mission to accelerate neurotechnology research, development and commercialization, including neuroscience companies, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. NIO's programs have the following goals: advocate the industry's position to regulators and elected officials; inform the media about industry's progress and contributions to quality of life; provide industry events and business development services to the industry; foster leadership positions that drive innovation forward.

About Cambridge Healthtech Institute (www.healthtech.com)
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, Next Generation Dx Summit and Discovery on Target. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.

About Cambridge Innovation Institute (www.CambridgeInnovationInstitute.com)
A vision since 1992: Cambridge Innovation Institute (CII) delivers cutting edge information through events, publishing, and training to leading commercial, academic, government and research institutes across the life science and energy industries. Cambridge Innovation Institute consists of two business areas: our coverage of advances in life sciences under the well-established Cambridge Healthtech Institute (CHI) brand, and coverage of rechargeable batteries under the newly established Cambridge EnerTech (CET) brand. We focus on high technology fields where research and development are essential for the advancement of innovation.